X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · IEX Real-Time Price · USD
0.754
-0.005 (-0.62%)
Jul 22, 2024, 10:27 AM EDT - Market open
X4 Pharmaceuticals Employees
X4 Pharmaceuticals had 93 employees as of December 31, 2023. The number of employees increased by 23 or 32.86% compared to the previous year.
Employees
93
Change (1Y)
23
Growth (1Y)
32.86%
Revenue / Employee
n/a
Profits / Employee
-$1,386,161
Market Cap
126.86M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 93 | 23 | 32.86% |
Dec 31, 2022 | 70 | -13 | -15.66% |
Dec 31, 2021 | 83 | 11 | 15.28% |
Dec 31, 2020 | 72 | 14 | 24.14% |
Dec 31, 2019 | 58 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Harvard Bioscience | 416 |
Agenus | 389 |
Veru Inc. | 189 |
Immunic | 77 |
Compass Therapeutics | 32 |
Relmada Therapeutics | 20 |
Annovis Bio | 16 |
Nuvectis Pharma | 13 |
XFOR News
- 25 days ago - X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial - GlobeNewsWire
- 4 weeks ago - 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More - Benzinga
- 6 weeks ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire